Walk-In-Interview for the following positions from In-House contractual employees of NHM working in the same post under the OSH&FW Society in other districts desiring to be posted in Puri District. The applications shall have the length of uninterrupted contractual service…
The Drugs Controller General of India (DCGI) will receive data from Eyestem for approval of a phase 2a first-in-human research for its product called Eyesight RPE for dry age-related macular degeneration (AMD). The approval will mark a key turning point…
The US Food and Drug Administration (FDA) has designated NTLA-2002 for the treatment of hereditary angioedema as a Regenerative Medicine Advanced Treatment (RMAT), according to Intellia Therapeutics, Inc., a leading clinical-stage genome editing business (HAE). NTLA-2002 is a CRISPR-based in…
An investigational new drug (IND) application for SNS-101, a conditionally active VISTA-blocking antibody, has been submitted to the US Food and Drug Administration (FDA) for a phase 1/2 clinical trial in patients with solid tumours, according to Sensei Biotherapeutics, Inc.,…
The Reserve Bank of India was set up on April 1, 1935. It is one of the few central banks to document its institutional history. So far, it has brought out four volumes of its history. Volume 1, covering the…
Intas is a leading, vertically integrated global pharmaceutical formulation development, manufacturing, and marketing company. Intas is committed to challenging the unmet medical and societal needs through a comprehensive pharmaceutical value chain spanning across the world. Intas has set up a…
Indian Medicines Pharmaceutical Corporation Limited (IMPCL) is established under Administrative control of Ministry of AYUSH, Govt. of India on 12th July 1978 with the prime object to manufacture and market the Genuine and Efficacious Indian System of Medicines to CGHS,…
The draught consensus statement for the treatment of urinary bladder cancer has been made public by the Indian Council of Medical Research (ICMR). Over a period of four weeks, from March 17 to April 14, 2023, the ICMR expert group’s…
The US Food and Drug Administration (FDA) has granted PBP1510 (international non-proprietary name: ulenistamab), a biopharmaceutical product manufactured by Singapore-based Prestige Biopharma, Fast Track designation for the treatment of metastatic or unresectable pancreatic adenocarcinoma (PDAC) that has relapsed after and/or…
First patient dosed in phase 1 clinical study (NCT05482893) of PT886, a first-in-class native IgG-like bispecific antibody (bsAb) targeting claudin 18.2 and CD47 for the treatment of gastric, gastroesophageal junction, and pancreatic adenocarcinomas, according to Phanes Therapeutics, Inc. (Phanes), an…
This will close in 0 seconds
